Grantham, Mayo, Van Otterloo & Co (GMO)’s Avanos Medical AVNS Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio AVNS Stock Details AVNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-19,590	Closed	-$501K	–	584
2023 Q2	$501K	Buy	19,590 +1,690	+9%	+$44.5K	﹤0.01%	558
2023 Q1	$532K	Buy	17,900 +10,200	+132%	+$296K	﹤0.01%	554
2022 Q4	$208K	Buy	+7,700	New	+$188K	﹤0.01%	676
2018 Q2	–	Sell	-13,900	Closed	-$641K	–	555
2018 Q1	$641K	Hold	13,900	–	–	﹤0.01%	440
2017 Q4	$642K	Buy	13,900 +7,400	+114%	+$340K	﹤0.01%	432
2017 Q3	$293K	Buy	6,500 +500	+8%	+$21.3K	﹤0.01%	482
2017 Q2	$236K	Buy	6,000 +300	+5%	+$11.3K	﹤0.01%	519
2017 Q1	$217K	Buy	+5,700	New	+$222K	﹤0.01%	533

Other funds holding AVNS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RGM Capital Naples, Florida $2.06B AUM 8.49% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

WHG

Westwood Holdings Group Dallas, Texas $13.7B AUM 21.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s AVNS Position: Q3 2023 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of Avanos Medical (AVNS) in Q3 2023, closing a stake of 19,590 shares — an estimated $501K sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in AVNS in Q1 2017 and held it in 8 quarters. The position peaked at $642K in Q4 2017. 260 funds tracked by Wall St. Rank hold AVNS as of Q3 2023.

Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining Avanos Medical position as of Q3 2023 after selling out during the quarter.
Grantham, Mayo, Van Otterloo & Co (GMO) sold 19,590 Avanos Medical shares in Q3 2023, an estimated $501K.
Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Avanos Medical in Q1 2017 and held it in 8 quarters.
Grantham, Mayo, Van Otterloo & Co (GMO)'s Avanos Medical position peaked at $642K in Q4 2017.
260 funds tracked by Wall St. Rank held Avanos Medical as of Q3 2023.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q3 2023, filed 13 Nov 2023.